Wall Street brokerages expect Sientra Inc (NASDAQ:SIEN) to report ($0.68) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Sientra’s earnings. The highest EPS estimate is ($0.61) and the lowest is ($0.74). Sientra posted earnings of ($0.92) per share during the same quarter last year, which suggests a positive year over year growth rate of 26.1%. The firm is expected to report its next quarterly earnings results on Tuesday, March 12th.
On average, analysts expect that Sientra will report full-year earnings of ($3.06) per share for the current fiscal year, with EPS estimates ranging from ($3.12) to ($2.98). For the next fiscal year, analysts expect that the company will post earnings of ($2.49) per share, with EPS estimates ranging from ($2.64) to ($2.34). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Sientra.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The business had revenue of $16.90 million during the quarter, compared to the consensus estimate of $16.66 million. Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The business’s revenue for the quarter was up 72.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.74) earnings per share.
Several analysts have weighed in on SIEN shares. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, September 27th. BidaskClub downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 21st. Finally, Stephens reissued a “buy” rating and issued a $30.00 price target on shares of Sientra in a research note on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $22.50.
Sientra stock opened at $18.00 on Tuesday. The company has a quick ratio of 2.34, a current ratio of 2.77 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $509.07 million, a price-to-earnings ratio of -6.38 and a beta of -0.42. Sientra has a twelve month low of $8.79 and a twelve month high of $26.79.
In related news, Director Timothy Haines sold 89,651 shares of the business’s stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the transaction, the director now owns 37,662 shares in the company, valued at $811,992.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 31.00% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY purchased a new stake in Sientra in the second quarter worth about $160,000. Accredited Investors Inc. purchased a new stake in Sientra in the third quarter worth about $200,000. Commonwealth Equity Services LLC purchased a new stake in Sientra in the second quarter worth about $210,000. MetLife Investment Advisors LLC purchased a new stake in Sientra in the second quarter worth about $226,000. Finally, Tarbox Family Office Inc. grew its holdings in Sientra by 595.3% in the third quarter. Tarbox Family Office Inc. now owns 9,734 shares of the medical instruments supplier’s stock worth $232,000 after purchasing an additional 8,334 shares during the period. Institutional investors own 87.01% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: Should You Consider an Index Fund?
Get a free copy of the Zacks research report on Sientra (SIEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.